Inovio Pharmaceuticals (NASDAQ:INO) had its price target upped by stock analysts at Royal Bank of Canada from $11.00 to $14.00 in a research report issued to clients and investors on Thursday, March 15th. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective would indicate a potential upside of 203.03% from the stock’s previous close.
INO has been the topic of several other research reports. Maxim Group dropped their target price on Inovio Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, February 15th. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, February 13th. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, BidaskClub upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, March 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. Inovio Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $19.07.
NASDAQ:INO traded down $0.18 during mid-day trading on Thursday, reaching $4.62. The stock had a trading volume of 709,399 shares, compared to its average volume of 1,187,007. The company has a market capitalization of $419.04, a price-to-earnings ratio of -4.24 and a beta of 2.51. Inovio Pharmaceuticals has a 1-year low of $3.76 and a 1-year high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Wednesday, March 14th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.06. The company had revenue of $8.80 million for the quarter, compared to analysts’ expectations of $9.13 million. Inovio Pharmaceuticals had a negative return on equity of 66.07% and a negative net margin of 208.92%. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.35) earnings per share. analysts expect that Inovio Pharmaceuticals will post -1.07 earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in INO. Virginia Retirement Systems ET AL acquired a new position in Inovio Pharmaceuticals during the 3rd quarter worth $101,000. Neuberger Berman Group LLC acquired a new position in Inovio Pharmaceuticals during the 3rd quarter worth $115,000. Engineers Gate Manager LP acquired a new position in Inovio Pharmaceuticals during the 3rd quarter worth $117,000. Teacher Retirement System of Texas acquired a new position in Inovio Pharmaceuticals during the 4th quarter worth $120,000. Finally, Belpointe Asset Management LLC acquired a new position in Inovio Pharmaceuticals during the 3rd quarter worth $150,000. 31.60% of the stock is owned by hedge funds and other institutional investors.
WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/08/inovio-pharmaceuticals-ino-pt-raised-to-14-00.html.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.